Antiplatelet drugs in secondary prevention of myocardial infarction: Clinical recommendations and perspective implications

Arnaldo Libretti, Vittorio Bertelé

Research output: Contribution to journalArticle

Abstract

Meta-analysis of several previous clinical trials, most of which were inconclusive, has recently ascertained the benefit of antiplatelet drugs in secondary prevention of myocardial infarction. This evidence has reoriented both pathogenetic and pharmacological views regarding, on the one hand, the relative role of platelets in thrombosis and in ischemic cardiovascular disease, and, on the other hand, the doubtful impact of inhibition of specific biochemical platelet targets on cardiovascular mortality. Data from meta-analysis and from more recent trials suggest that the clinical efficacy of antiplatelet drugs is likely related to their ability to interfere with thrombus formation. Although not dispelling the possibility of a concomitant antiatherosclerotic protection by antiplatelet treatment, this suggestion provides a useful guideline for the approach to primary prevention of cardiovascular mortality, in terms of treatment benefit expectancy, kind and size of population to test it, and type of drug to choose.

Original languageEnglish
Pages (from-to)S89-S91
JournalJournal of Cardiovascular Pharmacology
Volume14
Publication statusPublished - 1989

Keywords

  • Antiplatelet drugs
  • Clinical trials
  • Myocardial infarction
  • Primary prevention
  • Secondary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Antiplatelet drugs in secondary prevention of myocardial infarction: Clinical recommendations and perspective implications'. Together they form a unique fingerprint.

  • Cite this